Expression of interferon-γ and interferon-γ-inducible genes correlate with response to anti-PD-1/PD-L1 agents in primary melanoma and NSCLC: patients with both interferon-γ and PD-L1-positivity (as defined by greater than 25% of tumor cells) demonstrated the highest response rates [100, 102, 103]. This evidence concerns the gene PDCD1 and neoplasm.